Novasep Acquires Bioprocess Development Specialist Henogen

July 9, 2009

Novasep (Pompey, France), a producer of active pharmaceutical ingredients (APIs) and purification technologies for the life sciences industry, has acquired Henogen (Charleroi, Belgium), a contract manufacturing organization (CMO) offering bioprocess development and manufacturing services from the cell bank to the supply of clinical products. The move adds a complementary range of upstream processing capabilities and services to Novasep's downstream processing offering. Financial terms of the transaction were not disclosed.

Novasep (Pompey, France), a producer of active pharmaceutical ingredients (APIs) and purification technologies for the life sciences industry, has acquired Henogen (Charleroi, Belgium), a contract manufacturing organization (CMO) offering bioprocess development and manufacturing services from the cell bank to the supply of clinical products. The move adds a complementary range of upstream processing capabilities and services to Novasep’s downstream processing offering. Financial terms of the transaction were not disclosed.

As a result of this acquisition, Novasep customers will have access to manufacturing solutions covering almost every type of biopharmaceutical. In particular, Henogen brings its experience with an extensive array of expression tools including E. coli, yeast, L. lactis, insect and mammalian cells, and viral vectors. Novasep also will become one of the few CMOs that are able to provide a complete manufacturing solution in the rapidly growing field of antibody-drug conjugates, covering early development to future commercial production.

The two companies have already cooperated on several biomanufacturing projects and together have a strong portfolio of customers including Big Pharma, mid-size pharma and biotechs. Henogen has more than 100 employees and operates two biomanufacturing facilities south of Brussels. It will become a part of Novasep Process, Novasep’s biomolecules division.